Scully, Scott, Murphy & Presser, P.C.
EGFR and ALK dual inhibitor
The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.
PRECEDO PHARMACEUTICALS CO., LTD
A C C C A Y C C A A
A61K C07D C07D C07D A61P Y02P C07D C07D A61K A61K
inventional inventional inventional inventional inventional additional inventional inventional inventional inventional
Li Taoshan Qingsong Fengming Jing Wenchao Yongfei Ziping Zheng Beilei Aoli Jiaxin Hong
Wang Jiang Liu Zou Liu Wang Chen Qi Zhao Wang Wang Wu Wu